AR057915A1 - Compuesto con estructura de cinamida de dos ciclos con actividad inhibitoria de la produccion de abeta40 y abeta42, un agente farmaceutico que lo comprende y el uso de este en el tratamiento de enfermedades mentales y neurodegenerativas. - Google Patents
Compuesto con estructura de cinamida de dos ciclos con actividad inhibitoria de la produccion de abeta40 y abeta42, un agente farmaceutico que lo comprende y el uso de este en el tratamiento de enfermedades mentales y neurodegenerativas.Info
- Publication number
- AR057915A1 AR057915A1 ARP060105075A ARP060105075A AR057915A1 AR 057915 A1 AR057915 A1 AR 057915A1 AR P060105075 A ARP060105075 A AR P060105075A AR P060105075 A ARP060105075 A AR P060105075A AR 057915 A1 AR057915 A1 AR 057915A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- substituted
- substituents
- substituents selected
- alkyl
- Prior art date
Links
- 208000015122 neurodegenerative disease Diseases 0.000 title abstract 2
- 239000008177 pharmaceutical agent Substances 0.000 title abstract 2
- 230000002401 inhibitory effect Effects 0.000 title 1
- 230000003340 mental effect Effects 0.000 title 1
- 125000001424 substituent group Chemical group 0.000 abstract 18
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 8
- 125000005843 halogen group Chemical group 0.000 abstract 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 5
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 4
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 4
- 125000000000 cycloalkoxy group Chemical group 0.000 abstract 4
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000001841 imino group Chemical group [H]N=* 0.000 abstract 2
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 abstract 2
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 125000004076 pyridyl group Chemical group 0.000 abstract 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 abstract 2
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 abstract 1
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 102400000573 Amyloid-beta protein 40 Human genes 0.000 abstract 1
- 102400000574 Amyloid-beta protein 42 Human genes 0.000 abstract 1
- 201000010374 Down Syndrome Diseases 0.000 abstract 1
- 125000003277 amino group Chemical group 0.000 abstract 1
- 108010064397 amyloid beta-protein (1-40) Proteins 0.000 abstract 1
- 108010064539 amyloid beta-protein (1-42) Proteins 0.000 abstract 1
- FEWOUVRMGWFWIH-ILZZQXMPSA-N amyloid-beta polypeptide 40 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 FEWOUVRMGWFWIH-ILZZQXMPSA-N 0.000 abstract 1
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- -1 cinnamide structure compound Chemical class 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 230000000144 pharmacologic effect Effects 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- APEJMQOBVMLION-VOTSOKGWSA-N trans-cinnamamide Chemical group NC(=O)\C=C\C1=CC=CC=C1 APEJMQOBVMLION-VOTSOKGWSA-N 0.000 abstract 1
- 229920002554 vinyl polymer Polymers 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Un compuesto con estructura de cinamida de dos ciclos y a un agente farmacéutico que comprende el compuesto como componente activo. El compuesto con estructura de cinamida de dos ciclos está representado por al formula general (1) donde ----- representa un enlace simple o un doble enlace; Ar1 representa un grupo fenilo o un grupo piridinilo que puede estar sustituido con 1 a 3 sustituyentes; R1 y R2 cada uno representa un grupo alquilo C1-6, hidroxilo, o similares; Z representa metileno o vinileno, que puede estar sustituido con 1 o 2 sustituyentes seleccionados del grupo de sustituyentes A1, un átomo de O, o un grupo imino que puede estar sustituido con un sustituyente seleccionado del grupo de sustituyentes A1; y p, q y r cada uno representa un entero de 0 a 2, que posee un efecto que reduce la produccion de Abeta40 y Abeta42 y, por consiguiente, es especialmente util como agente profiláctico o terapéutico para una enfermedad neurodegenerativa causada por Abeta tal como la enfermedad de Alzheimer o el Síndrome de Down. Reivindicacion 1: Un compuesto representado por la formula (1) o una sal aceptable para uso farmacologico del mismo, donde ----- representa un enlace simple o un doble enlace; Ar1 representa un grupo fenilo que puede estar sustituido con 1 a 3 sustituyentes seleccionados del grupo de sustituyentes A1 o un grupo piridinilo que puede estar sustituido con 1 a 3 sustituyentes seleccionados del grupo de sustituyentes A1; R1 y R2 son iguales o diferentes y cada uno representa un grupo seleccionado del siguiente grupo de sustituyentes A1; Z1 representa un grupo metileno o grupo vinileno, que puede estar sustituido con 1 o 2 sustituyentes seleccionados del grupo de sustituyentes A1, un átomo de O, o un grupo imino que puede estar sustituido con un sustituyente seleccionado del grupo de sustituyentes A1; y p, q y r son iguales o diferentes y representan un entero de 0 a 2; Grupo de sustituyentes A1: (1) un átomo de halogeno, (2) un grupo hidroxilo, (3) un grupo ciano, (4) un grupo cicloalquilo C3-8, (5) un grupo cicloalcoxi C3-8, (6) un grupo alquilo C1-6, donde el grupo alquilo C1-6 puede estar sustituido con 1 a 3 sustituyentes seleccionados del grupo que consiste en un átomo de halogeno, grupo hidroxilo, grupo ciano, grupo cicloalquilo C3-8, grupo alcoxi C1-6 y grupo cicloalcoxi C3-8, (7) un grupo alcoxi C1-6, donde el grupo alcoxi C1-6 puede estar sustituido con 1 a 3 sustituyentes seleccionados del grupo que consiste en un átomo de halogeno, un grupo hidroxilo, grupo ciano, grupo cicloalquilo C3-8 y grupo cicloalcoxi C3-8, (8) un grupo amino que puede estar sustituido con uno o dos grupos alquilo C1-6, donde los grupos alquilo C1-6 pueden estar sustituidos con 1 a 3 átomos de halogeno, (9) un grupo carbamoílo que puede estar sustituido con uno o dos grupos alquilo C1-6, done los grupos alquilo C1-6 pueden estar sustituidos con 1 a 3 átomos de halogeno, (10) un grupo carboxilo, (11) un grupo alcoxicarbonilo C1-6, donde el grupo alcoxi C1-6 puede estar sustituido con 1 a 3 sustituyentes seleccionados del grupo que consiste en un átomo de halogeno, un grupo hidroxilo, un grupo ciano, un grupo cicloalquilo 3-8 y un grupo cicloalcoxi C3-8, (12) un grupo alquilo C1-6 y (13) un grupo alquilsulfonilo C1-6.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2005337963 | 2005-11-24 | ||
| JP2006205538 | 2006-07-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR057915A1 true AR057915A1 (es) | 2007-12-26 |
Family
ID=38067057
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060105075A AR057915A1 (es) | 2005-11-24 | 2006-11-20 | Compuesto con estructura de cinamida de dos ciclos con actividad inhibitoria de la produccion de abeta40 y abeta42, un agente farmaceutico que lo comprende y el uso de este en el tratamiento de enfermedades mentales y neurodegenerativas. |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US8048878B2 (es) |
| EP (1) | EP1953158B1 (es) |
| JP (1) | JP5178203B2 (es) |
| KR (1) | KR101296239B1 (es) |
| AR (1) | AR057915A1 (es) |
| AU (1) | AU2006317468B2 (es) |
| BR (1) | BRPI0618890A2 (es) |
| CA (1) | CA2629512C (es) |
| CR (1) | CR9983A (es) |
| EA (1) | EA014427B1 (es) |
| EC (1) | ECSP088466A (es) |
| ES (1) | ES2394364T3 (es) |
| GE (1) | GEP20115172B (es) |
| HN (1) | HN2008000792A (es) |
| MA (1) | MA29968B1 (es) |
| ME (1) | ME00040B (es) |
| MY (1) | MY144596A (es) |
| NO (1) | NO20082805L (es) |
| NZ (1) | NZ568422A (es) |
| PE (1) | PE20071029A1 (es) |
| PL (1) | PL1953158T3 (es) |
| RS (1) | RS20080242A (es) |
| SA (1) | SA06270432B1 (es) |
| TW (1) | TWI370130B (es) |
| WO (1) | WO2007060821A1 (es) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY149038A (en) | 2004-05-26 | 2013-07-15 | Eisai R&D Man Co Ltd | Cinnamide compound |
| AU2005297966B2 (en) | 2004-10-26 | 2010-12-23 | Eisai R & D Management Co., Ltd. | Amorphous object of cinnamide compound |
| TWI370130B (en) | 2005-11-24 | 2012-08-11 | Eisai R&D Man Co Ltd | Two cyclic cinnamide compound |
| EP1953154A4 (en) | 2005-11-24 | 2013-11-20 | Eisai R&D Man Co Ltd | CINNAMIDE COMPOUNDS OF MORPHOLINE TYPE |
| US7482345B2 (en) * | 2005-12-05 | 2009-01-27 | Meng-Hsin Chen | P38 kinase inhibiting agents |
| TWI378091B (en) | 2006-03-09 | 2012-12-01 | Eisai R&D Man Co Ltd | Multi-cyclic cinnamide derivatives |
| AR062095A1 (es) | 2006-07-28 | 2008-10-15 | Eisai R&D Man Co Ltd | Profarmaco de compuesto cinamida |
| US20080207900A1 (en) | 2007-02-28 | 2008-08-28 | Teiji Kimura | Two cyclic oxomorphorin derivatives |
| RU2009148866A (ru) * | 2007-06-01 | 2011-07-20 | Шеринг Корпорейшн (US) | Модуляторы гамма-секретазы |
| JP5121346B2 (ja) * | 2007-08-07 | 2013-01-16 | 国立大学法人 長崎大学 | 光学活性プロリンエステル誘導体およびｎ−ホルミル光学活性プロリン誘導体の製造方法 |
| US7935815B2 (en) * | 2007-08-31 | 2011-05-03 | Eisai R&D Management Co., Ltd. | Imidazoyl pyridine compounds and salts thereof |
| WO2009028588A1 (ja) | 2007-08-31 | 2009-03-05 | Eisai R & D Management Co., Ltd. | 多環式化合物 |
| CA2710485A1 (en) * | 2007-12-26 | 2009-07-02 | Eisai R&D Management Co., Ltd. | Process for production of 4-(substituted phenyl)hexahydropyrido[2,1-c][1,4]oxazin-6-one |
| EP2257541B1 (en) | 2008-02-22 | 2013-08-14 | F. Hoffmann-La Roche AG | Modulators for amyloid beta |
| MX2011003246A (es) | 2008-10-09 | 2011-04-21 | Hoffmann La Roche | Moduladores de beta amiloide. |
| WO2010054067A1 (en) * | 2008-11-06 | 2010-05-14 | Schering Corporation | Gamma secretase modulators |
| JP2012508180A (ja) * | 2008-11-06 | 2012-04-05 | シェーリング コーポレイション | γ−セクレターゼ調節剤 |
| WO2010052199A1 (en) | 2008-11-10 | 2010-05-14 | F. Hoffmann-La Roche Ag | Heterocyclic gamma secretase modulators |
| RU2011123862A (ru) * | 2008-11-13 | 2012-12-20 | Шеринг Корпорейшн | Модуляторы гамма-секретазы |
| CN102333777B (zh) | 2009-02-26 | 2014-06-25 | 卫材R&D管理有限公司 | 含氮的稠合杂环化合物及其作为β淀粉样蛋白生成抑制剂的用途 |
| AU2010218667A1 (en) | 2009-02-26 | 2011-07-21 | Eisai R&D Management Co., Ltd. | Salt of tetrahydrotriazolopyridine derivative and crystal thereof |
| JP2012176901A (ja) | 2009-09-25 | 2012-09-13 | Eisai R & D Management Co Ltd | 新規ベンゾニトリル化合物およびその製造方法 |
| US8486967B2 (en) | 2010-02-17 | 2013-07-16 | Hoffmann-La Roche Inc. | Heteroaryl substituted piperidines |
| SG186273A1 (en) * | 2010-06-15 | 2013-01-30 | Eisai R&D Man Co Ltd | Agent for treating hcv infection |
| JP6095208B2 (ja) * | 2012-12-04 | 2017-03-15 | 学校法人慶應義塾 | 環化化合物の製造方法、及び、環化化合物を含有する溶液の発光方法 |
| CN110383066B (zh) * | 2016-12-09 | 2023-03-31 | 戴纳立制药公司 | 化合物、组合物和方法 |
| WO2018213634A1 (en) * | 2017-05-17 | 2018-11-22 | Denali Therapeutics Inc. | Compounds, compositions and methods |
| JP7780440B2 (ja) * | 2019-10-07 | 2025-12-04 | ディー．イー．ショウ リサーチ，エルエルシー | Ｋｖ１．３カリウムシェーカーチャネル遮断薬としてのアリール複素二環式化合物 |
Family Cites Families (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4508718A (en) | 1984-01-16 | 1985-04-02 | Warner-Lambert Company | Cardiotonic and antihypertensive oxadiazinone compounds |
| DE3689506D1 (de) | 1985-10-09 | 1994-02-17 | Shell Int Research | Neue Acrylsäureamide. |
| US4783463A (en) | 1985-10-23 | 1988-11-08 | Rorer Pharmaceutical Corporation | Pyridyl-pyridazinone and pyridyl-pyrazolinone compounds and their use in the treatment of congestive heart failure |
| DE3541716A1 (de) | 1985-11-26 | 1987-05-27 | Celamerck Gmbh & Co Kg | Neue acrylsaeureamide |
| FI91754C (fi) | 1986-12-02 | 1994-08-10 | Tanabe Seiyaku Co | Analogiamenetelmä lääkeaineena käyttökelpoisen imidatsolijohdannaisen valmistamiseksi |
| IT1205834B (it) * | 1987-04-22 | 1989-03-31 | Elbart | Derivati tiodiossolanici ad attivita' mucolitica a procedimento per la loro preparazione |
| FI902321A7 (fi) | 1989-05-19 | 1990-11-20 | Eisai Co Ltd | Buteenihappojohdannaiset |
| JPH03206042A (ja) | 1990-01-06 | 1991-09-09 | Takeda Chem Ind Ltd | 降圧剤 |
| ES2100943T3 (es) | 1990-02-08 | 1997-07-01 | Eisai Co Ltd | Derivado de bencenosulfonamida. |
| AU680870B2 (en) * | 1993-04-28 | 1997-08-14 | Astellas Pharma Inc. | New heterocyclic compounds |
| GB9402807D0 (en) | 1994-02-14 | 1994-04-06 | Xenova Ltd | Pharmaceutical compounds |
| EP0784612A1 (en) | 1994-10-04 | 1997-07-23 | Fujisawa Pharmaceutical Co., Ltd. | Urea derivatives and their use as acat-inhibitors |
| JPH08283219A (ja) | 1995-04-07 | 1996-10-29 | Eisai Co Ltd | アラルキルアミノアルキルアミド誘導体 |
| PL329875A1 (en) | 1996-05-10 | 1999-04-12 | Icos Corp | Derivatives of carbolin |
| WO1998003166A1 (en) | 1996-07-22 | 1998-01-29 | Monsanto Company | Thiol sulfonamide metalloprotease inhibitors |
| WO1998024785A1 (en) | 1996-12-02 | 1998-06-11 | Fujisawa Pharmaceutical Co., Ltd. | Indole-urea derivatives with 5-ht antagonist properties |
| US6407129B1 (en) | 1997-03-31 | 2002-06-18 | Takeda Chemical Industries, Ltd. | Azole compounds, their production and their use |
| JP3108997B2 (ja) | 1997-03-31 | 2000-11-13 | 武田薬品工業株式会社 | アゾール化合物、その製造法および用途 |
| TW379224B (en) | 1997-12-02 | 2000-01-11 | Fujisawa Pharmaceutical Co | Urea derivatives |
| EP1051181B1 (en) | 1997-12-31 | 2004-03-17 | The University Of Kansas | Water soluble prodrugs of tertiary amine containing drugs and methods of making thereof |
| GB9816984D0 (en) | 1998-08-05 | 1998-09-30 | Smithkline Beecham Plc | Novel compounds |
| US6235728B1 (en) * | 1999-02-19 | 2001-05-22 | Bristol-Myers Squibb Company | Water-soluble prodrugs of azole compounds |
| PL349781A1 (en) | 1999-02-26 | 2002-09-09 | Merck & Co Inc | Novel sulfonamide compounds and uses thereof |
| WO2000051981A1 (en) | 1999-03-04 | 2000-09-08 | Nortran Pharmaceuticals Inc. | Aminocycloalkyl cinnamide compounds for arrhythmia and as analgesics and anesthetics |
| WO2001068585A1 (en) | 2000-03-14 | 2001-09-20 | Fujisawa Pharmaceutical Co., Ltd. | Novel amide compounds |
| US20010051642A1 (en) * | 2000-04-17 | 2001-12-13 | Kyunghye Ahn | Method for treating Alzheimer's disease |
| EP1278734A2 (en) | 2000-04-24 | 2003-01-29 | Merck Frosst Canada & Co. | Method of treatment using phenyl and biaryl derivatives as prostaglandin e inhibitors and compounds useful therefore |
| CZ20031795A3 (cs) * | 2000-12-04 | 2004-01-14 | F. Hoffmann-La Roche Ag | Fenylethenylové nebo fenylethynylové deriváty jako antagonisté glutamátového receptoru |
| GB0108770D0 (en) * | 2001-04-06 | 2001-05-30 | Eisai London Res Lab Ltd | Inhibitors |
| US7211575B2 (en) | 2001-09-13 | 2007-05-01 | Boehringer Ingelheim Pharmaceuticals, Inc. | Methods of treating cytokine mediated diseases |
| BR0212522A (pt) | 2001-09-14 | 2004-08-10 | Novo Nordisk As | Ligando de ligação de zinco, hexâmero de insulina, preparação aquosa de insulina e métodos de prolongar a ação de uma preparação de insulina e de preparar um ligando de ligação de zinco |
| CA2468544A1 (en) * | 2001-12-10 | 2003-06-19 | Amgen Inc. | Vanilloid receptor ligands |
| DK1465861T3 (da) * | 2001-12-20 | 2009-08-31 | Bristol Myers Squibb Co | Alpha-(N-sulfonamid)acetamidderivater som beta-amyloidhæmmere |
| JP2003206280A (ja) | 2001-12-28 | 2003-07-22 | Takeda Chem Ind Ltd | ビアリール化合物およびその用途 |
| WO2003062206A2 (en) | 2002-01-23 | 2003-07-31 | Arena Pharmaceuticals, Inc. | Small molecule modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related thereto |
| GB0207436D0 (en) | 2002-03-28 | 2002-05-08 | Glaxo Group Ltd | Novel compounds |
| US7053088B2 (en) * | 2002-05-22 | 2006-05-30 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
| EP2527315B1 (en) | 2002-05-31 | 2014-03-19 | Proteotech Inc. | Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as Alzheimer's disease, type 2 diabetes and Parkinson's disease |
| AU2003247758A1 (en) | 2002-06-27 | 2004-01-19 | Elan Pharmaceuticals, Inc. | Methods for treating alzheimer's disease using hydroxyethylene compounds containing a heterocyclic amide bond isostere |
| AU2003249937A1 (en) | 2002-07-12 | 2004-02-02 | Sanofi-Aventis Deutschland Gmbh | Heterocyclically substituted benzoylureas, method for their production and their use as medicaments |
| US6900354B2 (en) | 2002-07-15 | 2005-05-31 | Hoffman-La Roche Inc. | 3-phenyl-propionamido, 3-phenyl-acrylamido and 3-phenyl-propynamido derivatives |
| CA2514363A1 (en) * | 2003-02-12 | 2004-08-26 | Transtech Pharma, Inc. | Substituted azole derivatives as therapeutic agents |
| US7244739B2 (en) * | 2003-05-14 | 2007-07-17 | Torreypines Therapeutics, Inc. | Compounds and uses thereof in modulating amyloid beta |
| JP5010917B2 (ja) | 2003-08-29 | 2012-08-29 | エグゼリクシス， インコーポレイテッド | ｃ−Ｋｉｔ調節因子および使用方法 |
| EP1701959A1 (en) | 2003-12-22 | 2006-09-20 | Pfizer Limited | Triazole derivatives as vasopressin antagonists |
| WO2005072731A1 (en) | 2004-01-29 | 2005-08-11 | X-Ceptor Therapeutics, Inc. | 3-phenyl-n- ((1, 3, 4) thiadiazol-2-yl) -acrylamide derivatives and related compounds as modulators of estrogen-related receptors for the treatment of e.g. cancer, rheumatoid arthritis or neurological disorders |
| EP1730118A1 (en) | 2004-02-12 | 2006-12-13 | Transtech Pharma, Inc. | Substituted azole derivatives, compositions, and methods of use |
| MY149038A (en) * | 2004-05-26 | 2013-07-15 | Eisai R&D Man Co Ltd | Cinnamide compound |
| WO2006018662A2 (en) | 2004-08-16 | 2006-02-23 | Prosidion Limited | Aryl urea derivatives for treating obesity |
| AU2005297966B2 (en) * | 2004-10-26 | 2010-12-23 | Eisai R & D Management Co., Ltd. | Amorphous object of cinnamide compound |
| US20060241038A1 (en) | 2005-04-20 | 2006-10-26 | Eisai Co., Ltd. | Therapeutic agent for Abeta related disorders |
| WO2007034282A2 (en) | 2005-09-19 | 2007-03-29 | Pfizer Products Inc. | Diaryl-imidazole compounds condensed with a heterocycle as c3a receptor antagonists |
| CN101309916A (zh) * | 2005-11-18 | 2008-11-19 | 卫材R&D管理有限公司 | 制备肉桂酰胺衍生物的方法 |
| US20090048448A1 (en) * | 2005-11-18 | 2009-02-19 | Ikuo Kushida | Salts of cynnamide compound or solvates thereof |
| TWI370130B (en) | 2005-11-24 | 2012-08-11 | Eisai R&D Man Co Ltd | Two cyclic cinnamide compound |
| US20070117839A1 (en) * | 2005-11-24 | 2007-05-24 | Eisai R&D Management Co., Ltd. | Two cyclic cinnamide compound |
| EP1953154A4 (en) * | 2005-11-24 | 2013-11-20 | Eisai R&D Man Co Ltd | CINNAMIDE COMPOUNDS OF MORPHOLINE TYPE |
| TWI378091B (en) * | 2006-03-09 | 2012-12-01 | Eisai R&D Man Co Ltd | Multi-cyclic cinnamide derivatives |
| KR101464651B1 (ko) | 2006-03-09 | 2014-11-24 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 다환식 신나미드 유도체 |
| AR062095A1 (es) * | 2006-07-28 | 2008-10-15 | Eisai R&D Man Co Ltd | Profarmaco de compuesto cinamida |
| WO2008097538A1 (en) | 2007-02-08 | 2008-08-14 | Merck & Co., Inc. | Therapeutic agents |
| WO2008137102A2 (en) | 2007-05-04 | 2008-11-13 | Torreypines Therapeutics, Inc. | Methods of modulating amyloid beta and compounds useful therefor |
| AU2008248129B8 (en) | 2007-05-07 | 2013-05-30 | Merck Sharp & Dohme Corp. | Gamma secretase modulators |
| RU2009140182A (ru) * | 2007-05-11 | 2011-06-20 | Ф. Хоффманн-Ля Рош Аг (Ch) | Гетариланилины в качестве модуляторов для бета-амилоида |
| US8242150B2 (en) | 2007-06-13 | 2012-08-14 | Merck Sharp & Dohme Corp. | Triazole derivatives for treating alzheimer'S disease and related conditions |
| US20110009392A1 (en) | 2007-08-06 | 2011-01-13 | Schering Corporation | Gamma secretase modulators |
-
2006
- 2006-10-27 TW TW095139718A patent/TWI370130B/zh not_active IP Right Cessation
- 2006-11-01 GE GEAP200610709A patent/GEP20115172B/en unknown
- 2006-11-01 RS RSP-2008/0242A patent/RS20080242A/sr unknown
- 2006-11-01 BR BRPI0618890-7A patent/BRPI0618890A2/pt not_active IP Right Cessation
- 2006-11-01 JP JP2007546389A patent/JP5178203B2/ja not_active Expired - Fee Related
- 2006-11-01 EP EP06822806A patent/EP1953158B1/en active Active
- 2006-11-01 MY MYPI20081628A patent/MY144596A/en unknown
- 2006-11-01 AU AU2006317468A patent/AU2006317468B2/en not_active Ceased
- 2006-11-01 EA EA200801417A patent/EA014427B1/ru not_active IP Right Cessation
- 2006-11-01 CA CA2629512A patent/CA2629512C/en not_active Expired - Fee Related
- 2006-11-01 KR KR1020087014992A patent/KR101296239B1/ko not_active Expired - Fee Related
- 2006-11-01 ME MEP-2008-49A patent/ME00040B/me unknown
- 2006-11-01 PL PL06822806T patent/PL1953158T3/pl unknown
- 2006-11-01 WO PCT/JP2006/321877 patent/WO2007060821A1/ja not_active Ceased
- 2006-11-01 ES ES06822806T patent/ES2394364T3/es active Active
- 2006-11-01 NZ NZ568422A patent/NZ568422A/en not_active IP Right Cessation
- 2006-11-20 AR ARP060105075A patent/AR057915A1/es not_active Application Discontinuation
- 2006-11-21 PE PE2006001479A patent/PE20071029A1/es not_active Application Discontinuation
- 2006-11-22 SA SA6270432A patent/SA06270432B1/ar unknown
-
2008
- 2008-05-16 CR CR9983A patent/CR9983A/es not_active Application Discontinuation
- 2008-05-20 MA MA30952A patent/MA29968B1/fr unknown
- 2008-05-22 EC EC2008008466A patent/ECSP088466A/es unknown
- 2008-05-23 HN HN2008000792A patent/HN2008000792A/es unknown
- 2008-06-19 NO NO20082805A patent/NO20082805L/no not_active Application Discontinuation
-
2009
- 2009-03-13 US US12/403,565 patent/US8048878B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR057915A1 (es) | Compuesto con estructura de cinamida de dos ciclos con actividad inhibitoria de la produccion de abeta40 y abeta42, un agente farmaceutico que lo comprende y el uso de este en el tratamiento de enfermedades mentales y neurodegenerativas. | |
| AR081058A1 (es) | Derivados de arilmetoxi isoindolina, composiciones que los comprenden y su uso en el tratamiento del cancer. | |
| MX2020003415A (es) | Compuestos de benzoxacepina oxazolidinona y métodos de uso. | |
| UY37133A (es) | Derivados de pirazolo[1,5-a]pirazin-4-ilo | |
| AR087668A1 (es) | Derivados de oxazina y su uso en el tratamiento de enfermedades | |
| AR063602A1 (es) | Derivados de espiroindolinona, formulaciones farmaceuticas que los contienen y su uso en la obtencion de un medicamento para el tratamiento de trastornos oncologicos. | |
| NO20072978L (no) | Nye betuinderivater, preparat derav og anvendelse derav | |
| ATE541836T1 (de) | Polycyclische cinnamid-derivate | |
| AR059955A1 (es) | Compuestos policiclicos no peptidicos, medicamentos que los contienen, y usos para prevenir o tratar enfermedades causadas por la produccion de beta amiloide | |
| CL2008002542A1 (es) | Compuestos derivados de imidazolil piridina ligados a un heterociclo mediante un vinilo, moduladores de la actividad de amiloide-beta; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de enfermedades tales como alzheimer, demencia, sindrome de down o amiloidosis. | |
| JP2014511892A5 (es) | ||
| MX2019003143A (es) | Compuesto heterociclico sustituido con alquinilo, su metodo de preparacion y su uso medico. | |
| BR112015021983A8 (pt) | compostos heterocíclicos, composições e usos dos mesmos | |
| AR088175A1 (es) | 3-pirimidin-4-il-oxazolidin-2-onas utiles para tratar cancer y composiciones farmaceuticas que las contienen | |
| UY29963A1 (es) | Compuestos terapéuticos: piridinas y pirazinas como andamios | |
| RU2017118335A (ru) | Гетероциклическое производное, обладающее активирующей ampk активностью | |
| IN2014DN07283A (es) | ||
| AR084505A1 (es) | Derivados de 5-metil-1-(naftalen-2-il)-1h-pirazol | |
| JP2016500653A5 (es) | ||
| RU2009102270A (ru) | Производные тиазолилмочевины в качестве ингибиторов фосфатидилинозитол-3-киназы | |
| AR078120A1 (es) | Antagonistas de ccr3 de arilsulfonamida 2,5-disustituida y composiciones farmaceuticas | |
| WO2014085211A3 (en) | Spirocyclic sulfones as gamma secretase inhibitors | |
| NO20076396L (no) | Substituert akrylamidderivat og farmasoytisk preparat som omfatter dette | |
| BRPI0519267A2 (pt) | derivado de quinolina, seu uso, produÇço e medicamento contendo o mesmo | |
| UY38006A (es) | Inhibidores de la quinasa mtor, composiciones farmacéuticas que los contienen, y al uso en terapia de tales compuestos y composiciones |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |